Oncodesign Precision Medicine (FRA:ZR8) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Oncodesign Precision Medicine Cash Conversion Cycle Related Terms
Oncodesign Precision Medicine Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncodesign Precision Medicine Cash Conversion Cycle Chart
FRA:ZR8 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Oncodesign Precision Medicine's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's Cash Conversion Cycle falls into.
Oncodesign Precision Medicine Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 2,015.49 mean?
Oncodesign Precision Medicine (FRA:ZR8) has a Cash Conversion Cycle of 2,015.49 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Cash Conversion Cycle too high?
Oncodesign Precision Medicine's current Cash Conversion Cycle is 2,015.49. The Biotechnology industry median Cash Conversion Cycle is 103.69. Oncodesign Precision Medicine's value of 2,015.49 is 1843.8% above this industry median. Overall, Oncodesign Precision Medicine has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Cash Conversion Cycle compare to VRTX and REGN?
Oncodesign Precision Medicine's Cash Conversion Cycle of 2,015.49 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.69. Oncodesign Precision Medicine's value of 2,015.49 is 1843.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.69, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncodesign Precision Medicine's current Cash Conversion Cycle of 2,015.49 is 1843.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current Cash Conversion Cycle is 2,015.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current Cash Conversion Cycle is 2,015.49 and 1843.8% above the Biotechnology industry median of 103.69. Oncodesign Precision Medicine's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current Cash Conversion Cycle is 2,015.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for FRA:ZR8:
Cash Conversion Cycle: 2,015.49
GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
Industry Position: 1843.8% above the Biotechnology median
No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
38GF Score
Get the complete analysis for FRA:ZR8
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZR8 has been successfully added to your 
